Your browser doesn't support javascript.
loading
Pharmacological management of male breast cancer.
Duso, Bruno A; Trapani, Dario; Marra, Antonio; D'Amico, Paolo; Guerini Rocco, Elena; Fusco, Nicola; Mazzarella, Luca; Criscitiello, Carmen; Esposito, Angela; Curigliano, Giuseppe.
Afiliación
  • Duso BA; Division of Early Drug Development, European Institute of Oncology (IEO), IRCCS , Milan, Italy.
  • Trapani D; Department of Oncology and Hematology, University of Milan , Milan, Italy.
  • Marra A; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS , Milan, Italy.
  • D'Amico P; Division of Early Drug Development, European Institute of Oncology (IEO), IRCCS , Milan, Italy.
  • Guerini Rocco E; Division of Early Drug Development, European Institute of Oncology (IEO), IRCCS , Milan, Italy.
  • Fusco N; Department of Oncology and Hematology, University of Milan , Milan, Italy.
  • Mazzarella L; Division of Early Drug Development, European Institute of Oncology (IEO), IRCCS , Milan, Italy.
  • Criscitiello C; Department of Oncology and Hematology, University of Milan , Milan, Italy.
  • Esposito A; Department of Oncology and Hematology, University of Milan , Milan, Italy.
  • Curigliano G; Division of Pathology, European Institute of Oncology (IEO), IRCCS , Milan, Italy.
Expert Opin Pharmacother ; 21(12): 1493-1504, 2020 Aug.
Article en En | MEDLINE | ID: mdl-32496137
ABSTRACT

INTRODUCTION:

Despite its rarity, male breast cancer shows a steadily rising incidence. Given the absence of ad hoc prospective randomized clinical trials, treatment strategies are based on extrapolation from female breast cancer recommendations or solely on population-based data. AREAS COVERED This review discusses the current treatment landscape for male breast cancer in the adjuvant and in the metastatic setting. The authors also discuss the biology and genomic landscape of male breast cancer. Original research and review articles, relative to the period 2010-2019, were included in the review of the literature. EXPERT OPINION There is a major medical need to include male patients with breast cancer in prospective clinical trials. The call to equality in breast cancer care can be pursued via two divergent paths (i) a gender-neutral delivery of breast cancer information and (ii) the creation of separate sections, for the more common female breast cancer and for the rare male ones. We propose to differentiate male breast cancer care, acknowledging unique onco-sexual and social needs that can be only partially shared.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tamoxifeno / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de la Mama Masculina Tipo de estudio: Clinical_trials / Guideline Límite: Humans / Male Idioma: En Revista: Expert Opin Pharmacother Asunto de la revista: FARMACOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tamoxifeno / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de la Mama Masculina Tipo de estudio: Clinical_trials / Guideline Límite: Humans / Male Idioma: En Revista: Expert Opin Pharmacother Asunto de la revista: FARMACOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Italia